Covered recipient · General Payments record
JUSTIN L GRODIN
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
General Payments · PY2019–2024
$67,619.73
- Reported across 32 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $26,771.25 | 6 |
| Travel and Lodging | $10,247.69 | 3 |
| Food and Beverage | $340.64 | 3 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $23,425.74 | 5 |
| PFIZER INC. | $4,800.00 | 2 |
| Alexion Pharmaceuticals, Inc. | $3,510.00 | 1 |
| Novo Nordisk AS | $3,100.00 | 1 |
| Alnylam Pharmaceuticals Inc. | $2,380.00 | 1 |
| Acerta Pharma LLC | $143.84 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (12)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $3,510.00 | 01/09/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1094009665 | CMS |
| Alnylam Pharmaceuticals Inc. | $2,380.00 | 09/29/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1125828383 | CMS |
| AstraZeneca Pharmaceuticals LP | $91.51 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104459052 | CMS |
| AstraZeneca Pharmaceuticals LP | $52.33 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104361861 | CMS |
| Novo Nordisk AS | $871.08 | 05/27/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096551953 | CMS |
| Novo Nordisk AS | $12,981.25 | 05/27/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1096551955 | CMS |
| Novo Nordisk AS | $9,128.75 | 05/27/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096552143 | CMS |
| Novo Nordisk AS | $196.80 | 05/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096552301 | CMS |
| Novo Nordisk AS | $247.86 | 05/27/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096553399 | CMS |
| Novo Nordisk Inc | $3,100.00 | 12/04/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1097492488 | CMS |
| PFIZER INC. | $2,400.00 | 10/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131594767 | CMS |
| PFIZER INC. | $2,400.00 | 11/25/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131594763 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.